Huntington disease (HD) is a devastating neurodegenerative disorder caused by a CAG repeat expansion in the huntingtin gene. Disrupted cortico-striatal transmission is an early event that contributes to neuronal spine and synapse dysfunction primarily in striatal medium spiny neurons, the most vulnerable cell type in the disease, but also in neurons of other brain regions including the cortex. Although striatal and cortical neurons eventually degenerate, these synaptic and circuit changes may underlie some of the earliest motor, cognitive, and psychiatric symptoms. Moreover, synaptic dysfunction and spine loss are hypothesized to be therapeutically reversible before neuronal death occurs, and restoration of normal synaptic function may delay neurodegeneration. One of the earliest synaptic alterations to occur in HD mouse models is enhanced striatal extrasynaptic NMDA receptor expression and activity. This activity is mediated primarily through GluN2B subunitcontaining receptors and is associated with increased activation of cell death pathways, inhibition of survival signaling, and greater susceptibility to excitotoxicity. Abbreviations: AHA, azidohomoalanine; AP5, amino-5-phosphonovaleric acid; a competitive NMDA receptor antagonist; BACHD, Transgenic mouse model of Huntington disease containing the full-length human mutant huntingtin gene with 97 mixed CAA-CAG repeats; BDNF, brain-derived neurotrophic factor; C6R, Transgenic mouse model expressing full-length human mutant huntingtin bearing a point mutation at the D586 caspase cleavage site; CaMKII, calcium/calmodulindependent protein kinase II; CB, cerebellum; CK2, casein kinase 2; COS-7, fibroblast-like cell line derived from monkey kidney tissue; CREB, cAMP response element-binding protein; CS, cortico-striatal; CTX, cortex; cortical; DAPK1, death-associated protein kinase 1; DARPP32, dopamine-and cAMP-regulated neuronal phosphoprotein; DIV, day-in vitro; DKI, DAPK1 inhibitor; also referred to as TC